Drug Profile
ASP 4132
Alternative Names: ASP4132Latest Information Update: 24 May 2018
Price :
$50
*
At a glance
- Originator Astellas Pharma
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Lymphoma; Solid tumours
Most Recent Events
- 27 Apr 2018 Astellas Pharma completes a phase I trial in Lymphoma and Solid tumours (Second-line therapy or greater, Late-stage disease, Metastatic disease) in USA (PO) (NCT02383368)
- 01 Oct 2017 Discontinued - Phase-I for Lymphoma (Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (PO) (Astellas Pharma pipeline, November 2017)
- 01 Oct 2017 Discontinued - Phase-I for Solid tumours (Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (PO) (Astellas Pharma pipeline, November 2017)